## PATENT ASSIGNMENT

# Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:		NEW ASSIGNMENT			
NATURE OF CONVEYANCE:		ASSIGNMENT			
CONVEYING PARTY	DATA				
		Name	Execution Date		
CBA International, Inc	c. l		05/14/2012		
RECEIVING PARTY D	ΑΤΑ				
Name:	CBA Pharma, Inc.				
Street Address:	670 Perimeter				
City:	Lexington				
State/Country:	KENTUCKY				
Postal Code:	40517				
	RS Total: 9				
Property Type		Number			
Patent Number: 6218		541			
Application Number: 1293		9660		60185A4	
PCT Number: US		55437			
Patent Number: 5025		020			
Patent Number: 5332		747		¢360 00	
Patent Number: 6528		519			
Patent Number: 691		454			
Patent Number: 6124		315			
Patent Number: 6962		927			

### CORRESPONDENCE DATA

Fax Number:

 Email:
 patents@mitchelliplaw.com

 Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.

 Correspondent Name:
 Mitchell Intellectual Property Law, PLLC

 Address Line 1:
 1595 Galbraith Ave. SE

PATENT REEL: 028238 FRAME: 0871

501926985

Address Line 4: Grand Rapids, MICHIGAN 49546			
ATTORNEY DOCKET NUMBER:	CBA A000		
NAME OF SUBMITTER:	James A. Mitchell		
Total Attachments: 4 source=CBA_Assignment#page1.tif source=CBA_Assignment#page2.tif source=CBA_Assignment#page3.tif source=CBA_Assignment#page4.tif			

#### ASSIGNMENT

WHEREAS, CBA International, Inc. I, a corporation of the State of Delaware, having a place of business at 670 Perimeter, Lexington, KY 40517, hereinafter "CBA INTERNATIONAL" is the owner of record of the various United States and International patents and patent applications listed in Exhibit 1 hereto;

WHEREAS, the owner on some of the listed patents and patent applications is erroneously indicated as "CBA International, Inc.," rather than CBA International, Inc. I, through error and without deceptive intent;

WHEREAS, the owner of record of all of said patents which are assigned to CBA International, Inc. on their face should have been "CBA International, Inc. I;"

WHEREAS, CBA Pharma, Inc., a corporation of the State of Nevada, having a place of business at 670 Perimeter, Lexington, KY 40517, is desirous of acquiring of record all right, title and interest in and to all of said Exhibit 1 patents and patent applications;

NOW THEREFORE, in view of the above, and in view of other good and valuable consideration receipt of which is hereby acknowledged, CBA International Inc., I (a/k/a CBA International, Inc.) does hereby agree to sell, assign and transfer of record to CBA Pharma, Inc. all right, title and interest in and to all of said patents and patent applications listed in Exhibit 1 hereto.

This Assignment includes the right to collect any damages for past infringement of any of these patents.

Assignor hereby authorizes and requests the Patent Office Officials in the United States and in any and all foreign countries to issue any and all of said Letters Patent, when granted, to Assignee as the owner of the entire right, title and interest in and to the same, for the sole use and benefit of Assignee, its successors and assigns.

1

FURTHER, Assignor agrees to communicate to Assignee or its representatives any facts known to Assignor respecting the foregoing, and testify in any legal proceeding, sign all lawful papers, execute all divisional, continuation, continuation-in-part, substitution, renewal, and reissue applications, execute all necessary assignment papers to cause any and all of said Letters Patent to be issued to Assignee, make all rightful oaths and generally do everything possible to aid Assignee, its successors and assigns, to obtain and enforce proper protection for said patents in the United States and in any and all foreign jurisdictions.

## CBA INTERNATIONAL, INC. I

May 14, 2012

By W. Muhan Hatmann Michael Putnam, President

		EXHIBIT 1					
FILE NO.	PATENT NO.	APPLN. NO.	TITLE	PRIORITY DATE/FILING DATE	ISSUE DATE	EXPIRATION DATE	
P317USO-UTL	6,218,541		METHOD FOR EXTRACTING BISBENZYLISOQUINOLINES	6/28/1999	4/17/2001	6/28/2019	
			:	6/28/1999	4.1 1		
P319US1-UTL			ANTI-CANCER COMBINATIONAL THERAPY WHICH INHIBITS RESISTANCE	not filed			
			AND MINIMIZES TOXICITY				
P320US1-PRV			SUPERCRITICAL FLUID EXTRACTION OF BISBENZYL ISOQUINOLINES	not filed			
P356US2-UTL		12/939,660, Publ. No.	METHOD FOR EXTRACTING AND PURIFYING	11/05/2009	<u> </u>	11/4/2030	
		2011/0105755 publ. 05/05/2011	BISBENZYLISOQUINOLINES	11/04/2010			
P310AU0	673142		METHOD FOR POTENTIATING PRIMARY DRUGS IN TREATING MULTI DRUG RESISTANT CELLS	4/15/1992	2/18/1997	4/15/2012	
P310EP0	0 580 790		METHOD FOR POTENTIATING PRIMARY DRUGS IN TREATING MULTI	4/15/1992 4/15/1992	4/15/1992	4/15/2012	
			DRUG RESISTANT CELLS		•		
P356WO3		PCT/US10/554 37	METHOD FOR THE EXTRACTION OF BISBENZYLISOQUINOLINES	11/05/2009 11/4/2010		Term of any patent issuing on this PCT appln.	
		· · · · · · · · · · · · · · · · · · ·	D	age 1 of 2		11/4/2030	
				ADDOTCA			

4339764

PATENT REEL: 028238 FRAME: 0875

			EXHIBIT T	· · ·	
P300US0-UTL	5,025,020	USE OF TETRANDRINE AND ITS DERIVATIVES TO TREAT	9/28/1989	6/18/1991	9/28/2009
		MALARIA	9/28/1989		
P306US0-UTL 5,	5,332,747	METHOD FOR	6/13/1990	7/26/1994	7/26/2011
		POTENTIATING PRIMARY			
		DRUGS IN TREATING	6/13/1990		
		MULTIDRUG RESISTANT		· · .	
		PARASITIC DISEASE CELLS			
P309US0-DIV	6,528,519	USE OF TETRANDRINE AND	2/28/1991	3/4/2003	3/4/2020
		ITS DERIVATIVES TO TREAT			
		MALARIA	2/28/1991		
P312USO-CON	6,911,454	METHOD FOR	8/22/1994	6/28/2005	6/28/2022
		POTENTIATING PRIMARY			
		DRUGS IN TREATING			
		MULTIDRUG RESISTANT		. •	
		DISEASE			
P314USO-DIV	6,124,315	METHOD FOR	6/7/1995	9/26/2000	9/26/2020
		POTENTIATING PRIMARY			
		DRUGS IN TREATING			
		MULTIDRUG RESISTANT			
		DISEASE			
P315USO-DIV	6,962,927	METHOD FOR	6/7/1995	11/8/2005	11/8/2022
		POTENTIATING PRIMARY	· .		
		DRUGS IN TREATING			
		MULTIDRUG RESISTANT			
		DISEASE			· •

EXHIBIT 1

Page 2 of 2 4339764

# 12

# PATENT REEL: 028238 FRAME: 0876

RECORDED: 05/21/2012